RecruitingRecruiting
Psoriatic Immune Response to Tildrakizumab
NCT05390515 · University of California, San Francisco
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for tildrakizumab-corrected signatures.
Eligibility criteria
Inclusion Criteria:
* 18 years of age or older
* Patients with moderate-severe psoriasis or \> 5% body surface area affected.
Exclusion Criteria:
* taking systemic immunosuppressives in the last 4 weeks
* pregnancy
* severe immunodeficiency (either from genetic or infectious causes).
* tuberculosis or other active serious infection
* active systemic malignancy.
* breast-feeding
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Study design
Enrollment target: 10 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2022-09-01
Estimated completion: 2028-09-01
Last updated: 2026-06-04
Interventions
Drug: Tildrakizumab Prefilled Syringe
Primary outcomes
- • Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment (Baseline, 3 months)
Sponsor
University of California, San Francisco · other
With: Sun Pharmaceutical Industries Limited
Contacts & investigators
ContactRaymond Cho, MD, PhD · contact · rashes@ucsf.edu · 415-575-0524
InvestigatorRaymond Cho, MD, PhD · principal_investigator, University of California, San Francisco
All locations (1)
University of California, San FranciscoRecruiting
San Francisco, California, United States